Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > HemoBioTech’s CEO, Arthur Bollon, Ph.D., To Present At The NanoTX’07 Conference and Expo

Abstract:
HemoBioTech, Inc. (OTCBB: HMBT) announced today that Arthur Bollon, Ph.D., Chairman and Chief Executive Officer of HemoBioTech, will be presenting at the nanoTX ‘07 Conference and Expo in Dallas, Texas on Wednesday, October 3, 2007 at 10:30AM CST, at the Dallas Convention Center, Venue: A130-131. Dr. Bollon will make a presentation of the company's proprietary HemoTech™ blood substitute technology, recent developments, and commercial strategy.

HemoBioTech’s CEO, Arthur Bollon, Ph.D., To Present At The NanoTX’07 Conference and Expo

Dallas, TX | Posted on October 2nd, 2007

####

About nanoTX'07
nanoTX is one of the world’s most comprehensive nanotechnology conferences and exhibitions. The event highlights advances in nanoscience, explains how nanotechnology is being used today and how it will impact a broad range of industries tomorrow, including: biomedicine, electronics, energy, aerospace, defense, robotics, chemicals, and more.

nanoTX ’07 will involve over 150 nanotechnology specialists from 30 different countries and a special Nobel Laureates Legends reception. For more information, please click here http://www.nanotx.biz .

About HemoBioTech, Inc.

HemoBioTech is engaged in the development of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with ATP, adenosine, and GSH. HemoTech not only can carry oxygen in the blood, but can also induce erythropoiesis (red blood cell production). The company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities which have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. by prior holders of this technology. HemoTech is being subjected to further studies and testing to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com .

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech’s Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTech’s other reports filed with the Securities and Exchange Commission.

For more information, please click here

Contacts:
HemoBioTech, Inc.
Arthur P. Bollon, Ph.D.
Chief Executive Officer
972-455-8950

www.hemobiotech.com
or
Investor Relations:
The Investor Relations Group, Inc.
Christine Berni/Joseph Triunfo, 212-825-3210


or
Media:
Janet Vasquez/Michaela Heller, 212-825-3210

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Silver nanoparticles are toxic for aquatic organisms: A research team at the UPV/EHU-University of the Basque Country has analysed how zebrafish are affected in the long term by exposure to silver particles September 19th, 2018

Leti Announces EU Project to Develop Powerful, Inexpensive Sensors with Photonic Integrated Circuits: REDFINCH Members Initially Targeting Applications for Gas Detection and Analysis For Refineries & Petrochemical Industry and Protein Analysis for Dairy Industry September 19th, 2018

Events/Classes

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences August 31st, 2018

Stress-free ALD from Picosun August 28th, 2018

Kavli Lectures: New vision of nanomaterial synthesis and light-fueled space travel August 8th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project